"In terms of the rebate
rule, there's some question of whether this could be made effective for next
year, which is hard to envision given that bids are already submitted and the
Part D premiums are out."
— Tom Kornfield, senior consultant with Avalere Health, spoke
with AIS's RADAR on Medicare
Advantage about Trump's drug pricing executive orders, and what
their impact could be on the Part D program next year.
No comments:
Post a Comment